Evidence map›Paper›PMID 40795877›Full record

ArticleNeuro-oncology2025

The role of radiotherapy in MPNST and the impact of NF1 status on outcomes: Insights from a multicenter cohort study.

Christianne Y M N Jansma, Dirk J Grünhagen, Uta E Flucke, Willem-Bart M Slooff, Thijs van Dalen, Lukas B Been, Han J Bonenkamp, Monique H M E Anten, Martinus P G Broen, Marc H A Bemelmans and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Christianne Y M N JansmaDepartment of Plastic and Reconstructive Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0009-0000-5881-9316
Dirk J GrünhagenDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Uta E FluckeDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Willem-Bart M SlooffDepartment of Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Thijs van DalenDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Lukas B BeenDepartment of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Han J BonenkampDepartment of Surgical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Monique H M E AntenDepartment of Neurology, Maastricht University Medical Center+, Maastricht, The Netherlands.
Martinus P G BroenDepartment of Neurology, Maastricht University Medical Center+, Maastricht, The Netherlands.ORCID 0000-0002-8834-2202
Marc H A BemelmansDepartment of Surgical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands.
Jos A M BramerDepartment of Orthopedic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Gerard R SchaapDepartment of Orthopedic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Arthur J KievitDepartment of Orthopedic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Winan J van HoudtDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jos van der HageDepartment of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Michiel A J van de SandeDepartment of Orthopedic Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Courtney PendletonDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Robert J SpinnerDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
J Henk CoertDepartment of Plastic and Reconstructive Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-2417-7794
Cornelis VerhoefDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0001-9980-8613
Walter TaalDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-5530-7259
Enrico MartinDepartment of Plastic and Reconstructive Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive sarcomas, with 40% associated with neurofibromatosis type 1 (NF1). Surgical excision is the main treatment for localized disease; however, local recurrence (LR) remains high. Radiotherapy (RTx) is increasingly used to enhance local control in STS, but its use remains controversial due to the potential for increased major wound complications and an increased risk of secondary malignancies in NF1 patients. This study investigated the use and impact of RTx on local control in MPNSTs, particularly in the NF1 setting.

methodsSurgically treated primary MPNSTs from 1988 to 2019 in the MONACO multicenter cohort were included. Differences in demographics, treatment, and RTx use between NF1 and non-NF1 cases were examined. Factors influencing RTx administration and LR were assessed via multivariable analyses.

resultsAmong 499 patients (33.1% NF1), 143 (28.7%) experienced LRs. Radiotherapy was administered to 56.3% of patients (57.0% in the NF1 group), with 27.3% receiving neoadjuvant and 72.7% adjuvant RTx. RTx was administered significantly more often to high-grade and extremity tumors. While RTx did not affect overall survival, it reduced LR risk in sporadic cases (hazard ratio [HR] 0.530; 95% confidence interval [CI], 0.354-0.793) but not in the NF1 subgroup (HR 1.00; 95% CI, 0.545-1.85). In NF1 patients, a microscopically positive margin (R1) was the only risk factor for LR development (HR 2.1; 95% CI, 1.19-3.79).

conclusionsRTx is frequently used in the treatment of MPNSTs, regardless of NF1 status. While it may affect the LR rate in sporadic cases, its impact on NF1 patients is less clear.

Indexed as

Neoplasm Recurrence, LocalNeurofibromatosis 1AdolescentAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung Adultlocal recurrencemalignant peripheral nerve sheath tumorsneurofibromatosis type 1radiotherapysoft tissue sarcoma

Identifiers

PMID40795877
PMCPMC12916730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.